Cytek Investor Presentation Deck
Disclaimer
This presentation and the accompanying oral presentation contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including,
among others, statements regarding the size and growth of the cell analysis market; Cytek's anticipated total addressable market; Cytek's business and operational strategy;
Cytek's prospective products; Cytek's business development plans and opportunities; Cytek's anticipated customer mix and collaborations plans; and objectives of management for
future operations are forward looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our
current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy, and
financial needs. All statements other than statements of historical facts contained in this presentation, including, without limitation, statements The words "may," "will," "expect,"
"anticipate," "aim,” “estimate,” “intend," "plan," "believe," "is/are likely to," "potential," "continue" and other similar expressions are intended to identify forward-looking statements,
although not all forward-looking statements contain these identifying words.
Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including but not
limited to risks relating to market conditions; the ongoing COVID-19 pandemic; Cytek's dependence on certain sole and single source suppliers; competition; market acceptance of
Cytek's current and potential products; Cytek's ability to manage the growth and complexity of its organization; Cytek's ability to maintain, protect and enhance its intellectual
property; and Cytek's ability to continue to stay in compliance with its material contractual obligations, applicable laws and regulations. Information on these and additional risks and
uncertainties and other information affecting Cytek's business and operating results is contained in Cytek's Quarterly Report on Form 10-Q for the quarter ended June 30, 2021,
and in its other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Except as required by applicable law,
Cytek does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed
circumstances or otherwise. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.
Certain information contained in this presentation and statements made orally during this presentation relate to or are based on studies, publications, surveys and other data
obtained from third-party sources and Cytek's own internal estimates and research. While Cytek believes these third-party sources to be reliable as of the date of this presentation,
it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. While
Cytek believes its internal research is reliable, such research has not been verified by any independent source. Cytek's estimates are derived from publicly available information,
management's knowledge of the Cytek's industry and management's assumptions based on such information and knowledge, which they believe to be reasonable. This data
involves a number of assumptions and limitations which are necessarily subject to a high degree of uncertainty and risk due to a variety of factors.
Cytek, cFluor, Full Spectrum Profiling, FSP, Northern Lights, Similarity and Complexity are trademarks or registered trademarks of Cytek Biosciences, Inc. Other trademarks
appearing in this presentation are the property of their respective holders.
CYTEK
TRANSCEND THE CONVENTIONAL
NView entire presentation